Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich.  To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich. To take the survey, visit: https://bit.ly/BiomarkerS24

LCC in Portuguese: Barriers to Biomarker Testing

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share LCC in Portuguese: Barriers to Biomarker Testing

Sign up to save your podcasts

LCC in Portuguese: Barriers to Biomarker Testing

LCC in Portuguese: Barriers to Biomarker Testing

More shows like Lung Cancer Considered

Lung Cancer Update

Freakonomics Radio

NEJM This Week

Hidden Brain

ASCO Daily News

The Daily

Today, Explained

ASCO Guidelines

OncLive® On Air

Plenary Session

Oncology Today with Dr Neil Love

Conversations in Lung Cancer Research

The Ezra Klein Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions